Jci_page_head_homepage_01 Jci_page_head_homepage_02
Swarnali Acharyya, Katherine J. Ladner, Lori L. Nelsen, Jeffrey Damrauer, Peter J. Reiser, Steven Swoap, Denis C. Guttridge
Published in Volume 114, Issue 3
J Clin Invest. 2004; 114(3):370–378 doi:10.1172/JCI20174
Abstract | Full text | PDF | Supplemental material
Options: View larger image (or click on image)
Jci0420174
Figure 6

C-26 tumors enhance ubiquitin/E3 ligase expression and MyHC ubiquitination products. Mice were injected in the right flank with either control (n = 3) or C-26 cells (n = 3), and at days 23–25 after injection, tibialis muscles were isolated and prepared for RNA or protein analyses. (A) Northern blots probing for ubiquitin (Ub), MuRF1, and atrogin-1/MAFbx in muscles from control versus C-26–injected mice. (B and C) Homogenates were prepared from mouse muscles or C2C12 myotubes, and protein complexes were subsequently immunoprecipitated overnight with an anti-ubiquitin antibody (IP). Immunoprecipitates were fractionated by SDS-PAGE, and immunoblot (IB) analyses probing for MyHC (upper panels) or tropomyosin (TM; lower panels) were performed. The Western blot for MyHC in B was purposely overexposed to accentuate differences in MyHC protein products coupled to ubiquitin (bracketed). Asterisks in the tropomyosin Western blot denote nonspecific bands. (D and E) Homogenates described in B and C were immunoprecipitated with an α-sarcomeric actin antibody (IP), and complexes were fractionated by SDS-PAGE and immunoblotted (IB) for MyHC and α-actin.